AI made execution free. Knowing first is the whole game now.
The advantage goes to whoever is first into the right conversations, most often. Fundz stacks those odds: more of the moments that create demand than anyone else catches, as they happen, matched to who you sell to, with the decision maker to call. Now it answers in Claude too: ask for today’s leads and who to reach, then write the note in the same window. Not a feed. Not a list you rent. A system for being first.
Trusted by
OracleSnowflakeCloudflareLinkedInGoogleSalesforce
★★★★★4.8/5 on G2· Since 2015
Gaomei Gene advances new financing round backed by Gaoxin Venture Capital following Pre-A funding of tens of millions of yuan.
Gaomei Gene, a tumor epigenetics company, has advanced to a new round of financing backed by Gaoxin Venture Capital. The company previously completed a Pre-A round of tens of millions of yuan in July 2020 with the same investor. Gaomei Gene focuses on whole-genome DNA methylation detection and AI algorithms for early tumor screening and detection. The company aims to reduce costs and usage thresholds for multi-cancer early screening through its methylation chip technology.
Company Information
Company
Gaomei Gene
Location
China
About
Gaomei Gene focuses on tumor epigenetics, utilizing whole-genome DNA methylation detection and self-developed AI algorithms to build a comprehensive product system for early tumor screening, companion diagnosis, dynamic monitoring, and prognosis assessment. The company is developing an AI-driven methylation pan-cancer early screening gene chip to reduce costs and lower usage thresholds for multi-cancer screening. Their technology can detect tumors across 12 organs using a single chip with high sensitivity and specificity. Gaomei Gene has established a Chinese population whole-genome methylation database and completed Class I medical device declarations for their early cancer screening products.
Fundz sees it the moment Gaomei Gene raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
ChinaBiotechnologyHealth CareArtificial IntelligenceGeneticsTherapeuticsHealth Diagnostics